Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmesis International Ltd. ( (SG:BFK) ) has issued an update.
Pharmesis International Ltd. reported a return to profitability in FY2024 with a net profit of RMB8.3 million, driven by a 48.2% increase in revenue to RMB67.6 million. This growth was largely attributed to the new TCH procurement segment, which contributed significantly in its first half-year. The company leverages its experience and established network to maintain a competitive edge in sourcing herbs directly from local farmers in Sichuan. The entry into this segment did not materially change the group’s risk profile, as it aligns with their existing expertise. Additionally, Mr. Chew Heng Ching was redesignated as non-Independent non-executive chairman, stepping down from his roles as chairman of key committees but remaining a member.
More about Pharmesis International Ltd.
Pharmesis International Ltd. operates in the pharmaceutical industry, focusing on the procurement and distribution of Traditional Chinese Herbs (TCH). The company sources herbal medicines from Sichuan, China, and processes and distributes them through its established industry network.
Average Trading Volume: 8,738
Technical Sentiment Signal: Sell
Current Market Cap: S$18.39M
For a thorough assessment of BFK stock, go to TipRanks’ Stock Analysis page.